Lineage of origin in rhabdomyosarcoma informs pharmacological response.

  title={Lineage of origin in rhabdomyosarcoma informs pharmacological response.},
  author={Jinu Abraham and Yaiza N{\'u}{\~n}ez-{\'A}lvarez and Simone Hettmer and Elvira Carri{\'o} and Hung-I Harry Chen and Koichi Nishijo and Elaine T Huang and Suresh I. Prajapati and Robert L. Walker and Sean Davis and Jennifer Rebeles and Hunter Wiebush and Amanda T. McCleish and Sheila T. Hampton and Christopher R. R. Bjornson and Andrew S. Brack and Amy J. Wagers and Thomas A Rando and Mario R Capecchi and Frank C. Marini and Benjamin R Ehler and Lee Ann Zarzabal and Martin W Goros and Joel E. Michalek and Paul S. Meltzer and David M Langenau and Robin D Legallo and Atiya Mansoor and Yidong Chen and M{\`o}nica Suelves and Brian P. Rubin and Charles Keller},
  journal={Genes & development},
  volume={28 14},
Lineage or cell of origin of cancers is often unknown and thus is not a consideration in therapeutic approaches. Alveolar rhabdomyosarcoma (aRMS) is an aggressive childhood cancer for which the cell of origin remains debated. We used conditional genetic mouse models of aRMS to activate the pathognomonic Pax3:Foxo1 fusion oncogene and inactivate p53 in several stages of prenatal and postnatal muscle development. We reveal that lineage of origin significantly influences tumor histomorphology and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
23 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…